MOBERG DERMA SIGNS DISTRIBUTION AGREEMENT IN AUSTRALIA AND NEW ZEELAND Moberg Derma AB (publ.) has entered into a distribution agreement with OzHealth Pharma for Emtrix® - for discolored and damaged nails caused by nail fungus (onychomycosis) or nail psoriasis. Under the agreement OZ Pharma Health is granted exclusive rights to market and sell Emtrix® in Australia and New Zeeland. ”The agreement is part of our international commercialization of Emtrix®, which now will be marketed in another large market. We currently have secured distributors for Emtrix® in over 20 markets,” comments Moberg Derma's CEO, Peter Wolpert. About Emtrix® and nail diseases Emtrix® is a prescription free, topical nail product and has the potential to become first-line treatment for common nail disorders. Launch of Emtrix® was initiated in the first markets in September 2010. Safety and efficacy have been demonstrated in several clinical studies including more than 500 patients. Emtrix® has a unique and rapid mechanism of action which brings visible improvements within 2-4 weeks of treatment. Nail fungus is the most common nail disease and afflicts approximately 10% of the general population and increasing with age. The estimated global market potential exceeds USD 1 billion. The untapped potential is significant since many patients remain untreated. It is generally recognized that there is a need for new efficacious and safe topical treatments. For further information, please contact: Peter Wolpert, President and CEO of Moberg Derma Telephone: +46 8 522 307 00 Mobile: +46 735 71 35 E-mail: peter.wolpert@mobergderma.se (peter.wolpert@mobergderma.se) Magnus Persson, IR Mobile: +46 73-355 26 01 E-mail: magnus.persson@mobergderma.se (magnus.persson@mobergderma.se) Moberg Derma discloses the information provided herein pursuant to the Securities Markets Act and/or the Financial Instruments Trading Act. The information was submitted for publication on 8 June, 08:00 am.
MOBERG DERMA SIGNS DISTRIBUTION AGREEMENT IN AUSTRALIA AND NEW ZEELAND
| Source: Moberg Pharma AB